BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Imprime PGG: Preliminary Phase Ib/II data

Data from 10 patients in the first arm of an open-label, dose-escalation Phase Ib/II trial showed that 2, 4 and 6 mg/kg Imprime PGG plus Erbitux cetuximab and irinotecan as second- or third-line therapy resulted in 3 partial responses and 7 cases of stable disease. Median...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >